Taking it

The recommended dose of fosamprenavir (Telzir) in the European Union is 700mg with 100mg ritonavir (Norvir) twice daily in combination with at least two other antiretroviral drugs. In Europe, it is only approved for treatment-experienced patients.

BHIVA guidelines advise boosted fosamprenavir dosed twice daily at FPV700/r 100mg for all adult patients.

Fosamprenavir (FPV) is licensed in the United States for treatment-naive or -experienced patients. Dosing for those who are antiretroviral naive is at the following dosages:

  • 1400mg FPV twice a day.
  • 1400mg boosted with 200mg ritonavir once daily in people who have not previously taken protease inhibitors.
  • 1400mg boosted with 100mg ritonavir, both once daily.
  • 700mg with 100mg of ritonavir, both taken twice daily.

In antiretroviral-experienced patients, the recommended dose is 700mg FPV with 100mg ritonavir, both taken twice daily.

The use of a higher fosamprenavir dose in highly treatment-experienced patients is being investigated. Preliminary safety data suggest that boosting of 1400mg twice daily with 200mg of ritonavir is poorly tolerated.1 Boosting of 1400mg fosamprenavir with 100mg ritonavir twice daily is still being investigated but no efficacy data are available.

Tablets can be taken with or without food. Adults using the oral solution should take it without food, but paediatric patients need to take the oral suspension with food.2 Oral suspension does not require refrigeration; shake well before using.

Fosamprenavir is available in 700mg tablets and as a liquid at a concentration of 50mg/ml.

References

  1. Shelton MJ et al. Pharmacokinetic and safety evaluation of high dose combinations of fosamprenavir and ritonavir (APV10028). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, abstract A-451, 2004
  2. Wire MB et al. Evaluation of plasma amprenavir pharmacokinetics following administration of fosamprenavir formulations with a high fat breakfast (APV10008). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, abstract A-448, 2004
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.